Stay Updated with the Latest argenx SE ARGX News in Real Time
Find ARGX news now at Meyka AI. Stay informed with the latest argenx SE stocks updates, including price news, market analysis, and expert insights.
ARGX argenx SE Earnings Preview May 7, 2026
argenx SE (ARGX) reports Q1 2026 earnings May 7. Analysts expect $5.16 EPS and $1.31B revenue. Stock rated B+ by Meyka AI.
ARGX.BR argenx SE Earnings Preview May 7, 2026
argenx SE earnings preview: EPS estimate $4.23, revenue $957.29M expected May 7. Biotech stock analysis.
Cowen Maintains Buy on argenx SE (ARGX) March 13, 2026
Cowen maintains Buy on argenx SE; our ARGX analyst rating review covers implications, price move, and Meyka Grade A
Maintained Buy by BofA on ARGX argenx SE Feb 2026
BofA maintained Buy and raised ARGX price target to $1,013 — ARGX analyst rating update and implications
Argenx Releases H1 2025 Financials and Q2 Business Highlights
Argenx, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, has published its first-half 2025 financial results and second-quarter business highlights. The company’s robust pipeline development and strategic partnerships continue to shape its position as a biotech leader in rare diseases. Strong Revenue Growth Driven by Vyvgart Franchise…